Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 29;16(4):2120-2131.
doi: 10.14336/AD.2024.0950.

Common Characteristics Between Frailty and Myotonic Dystrophy Type 1: A Narrative Review

Affiliations
Review

Common Characteristics Between Frailty and Myotonic Dystrophy Type 1: A Narrative Review

Joana Garmendia et al. Aging Dis. .

Abstract

Myotonic dystrophy type 1 (DM1) is an inherited neuromuscular disorder often considered a model of accelerated aging due to the early appearance of certain age-related clinical manifestations and cellular and molecular aging markers. Frailty, a state of vulnerability related to aging, has been recently studied in neurological conditions but has received considerably less attention in neuromuscular disorders. This narrative review aims to describe 1) the common characteristics between Fried's frailty phenotype criteria (muscular weakness, slow gait speed, weight loss, exhaustion/fatigue, and low physical activity) and DM1, and 2) the psychological and social factors potentially contributing to frailty in DM1. This review gathered evidence suggesting that DM1 patients meet four of the five frailty phenotype criteria. Additionally, longitudinal studies report the deterioration of these criteria over time in DM1. Patients also exhibit psychological/cognitive and social factors that might contribute to frailty. Monitoring frailty criteria in the DM1 population could help to implement timely preventions and interventions to reduce the disease burden and severity of frailty symptoms.

PubMed Disclaimer

References

    1. Harper P Myotonic dystrophy., 3rd ed. Saunders: London, UK; 2001.
    1. Hunter A, Tsilfidis C, Mettler G, Jacob P, Mahadevan M, Surh L, et al. (1992). The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. J Med Genet, 29:774-779. - PMC - PubMed
    1. Wenninger S, Cumming SA, Gutschmidt K, Okkersen K, Jimenez-Moreno AC, Daidj F, et al. (2021). Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1. Neurol Genet, 7:e572. - PMC - PubMed
    1. Thornton CA (2014). Myotonic Dystrophy. Neurol Clin, 32:705-719. - PMC - PubMed
    1. Turner C, Hilton-Jones D (2014). Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol, 27:599-606. - PubMed

LinkOut - more resources